ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: SA-PO670

The Effect of Far-Infrared Therapy on the Cardiovascular and Infection Events in Peritoneal Dialysis Patients

Session Information

  • Home Dialysis - II
    November 04, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

  • 802 Dialysis: Home Dialysis and Peritoneal Dialysis


  • Lin, Chih-Ching, Taipei Veterans General Hospital Department of Internal Medicine, Taipei, Taiwan

Group or Team Name

  • Taipei VGH PD Team.

Long-term peritoneal dialysis (PD) may be associated with cardiovascular (CV) and infection complications. A previous case reprt has shown that far-infrared (FIR) therapy may improve abdominal discomfort due to encapsulating peritoneal sclerosis in PD patients. Since there is little information concerning this issue, we conducted this study in order to evaluate the possible effects of FIR therapy on the CV and infection events of PD patients.


A total of 99 PD patients were enrolled and randomly divided into FIR and control groups. WS TY101 FIR emitter (WS Far Infrared Medical Technology Co., Taipei, Taiwan) was used to conduct the FIR therapy. The irradiating power density was set at 20 mW/cm2 and the top radiator was set at 20 cm above the abdomen. Both groups underwent FIR therapy for 40 minutes twice daily during the first and last exchange of each PD session for 1 year. The outcome measures include (1) CV events such as 3P-MACE (3-point major adverse cardiovascular events [consisting of non-fatal stroke, myocardial infarction, and CV death]), coronary artery disease (CAD), and hospitalized heart failure (HHF) and (2) infection events such as pneumonia and peritonitis.


Peritonitis was found to be statistically significant (hazard ratio (HR)=0.418, P=0.017) while two combinations of events were also found to be significant (CV and infection events [HR=0.338, P=0.007] & CV events and peritonitis [HR=0.336, P=0.012]). The survival curves showed that the FIR group had a slower occurrence of CV and infection events, as well as CV events and peritonitis, than the control group. The log-rank tests for both CV and infection events & CV events and peritonitis showed a significant difference (P=0.005, 0.007, respectively) between the two groups.


FIR therapy may significantly lower the risk of CV and infection events, as well as CV and peritonitis events.

Event TypeControl N=50FIR N=49HRP
3P-MACE, CAD, and HHF7 (14)8 (16.33)0.2700.103
Peritonitis14 (28)11 (22.45)0.4180.017*
CV and infection events19 (38)17 (34.69)0.3380.007*
CV events and peritonitis17 (34)17 (34.69)0.3360.012*


  • Government Support – Non-U.S.